Selective PRMT5 Inhibitors Suppress Human CD8+ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA
Carolin Dorothea Strobl(Friedrich-Alexander-Universität Erlangen-Nürnberg), Michael Aigner(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 35
Related Papers
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series
|The Lancet Rheumatology|2024|96
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study
|The Lancet Rheumatology|2025|71
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells
|Nature Medicine|2025|60
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma
|Blood|2025|27
Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells
|The Lancet|2024|26